1.	Phase III Randomized Study of Donepezil and Vitamin E in the Prevention of Cognitive Dysfunction Following Cancer Treatment That Included Prophylactic Cranial Irradiation in Patients With Small Cell Lung Cancer Phase: Phase III Type: Supportive care Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: NCCTG-N99C5, NCI-P00-0169, NCT00006349
2.	Phase III Randomized Study of Donepezil Hydrochloride in Patients Who Have Undergone Partial- or Whole-Brain Irradiation for Brain Tumors Phase: Phase III Type: Supportive care Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: CCCWFU-91105, WFU 91105°, NCT00369785, WFU-91105
3.	Efficacy and Safety of Donepezil Hydrochloride in Preadolescent and Adolescent Children With Attention Impairment Following Cancer Treatment Phase: Phase III Type: Supportive care Status: Completed Age: 6 to 17 Sponsor: Pharmaceutical / Industry Protocol IDs: E2020-G000-333, NCT00688376
4.	Donepezil or EGb761 in Improving Neurocognitive Function in Patients Who Have Previously Undergone Radiation Therapy for Primary Brain Tumor or Brain Metastases Phase: Phase II Type: Supportive care Status: Completed Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000330114, CCCWFU-97100, CCCWFU-BG00-225, NCT00070161
5.	Donepezil in Treating Young Patients With Primary Brain Tumors Previously Treated With Radiation Therapy to the Brain Phase: No phase specified Type: Supportive care Status: Closed Age: 8 to 17 Sponsor: NCI, Other Protocol IDs: CDR0000537049, P30CA012197, CCCWFU-91305, CCCWFU-IRB-00000258, NCT00452868
6.	Adjunctive Donepezil Therapy and Genetic Risk Factors of Cognitive Dysfunction in Brain Tumor Survivors Phase: No phase specified Type: Supportive care Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: 04-122, NCT00594633